The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. (2013)

First Author: Sale MJ
Attributed to:  How does ERK1/2-dependent phosphorylation target BimEL to the proteasome? funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1042/bj20121212

PubMed Identifier: 23234544

Publication URI: http://europepmc.org/abstract/MED/23234544

Type: Journal Article/Review

Volume: 450

Parent Publication: The Biochemical journal

Issue: 2

ISSN: 0264-6021